Stephan F. Taylor

Dr. Stephan F. Taylor


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in NeuroImage
Verified
Journal Article
Closed access
KPK.Luan Phan
K.Luan Phan
TWTor Wager
Tor Wager
STStephan F. Taylor
Stephan F. Taylor
ILIsrael Liberzon
Israel Liberzon

1 July 2003 in NeuroImage
Verified
Journal Article
Closed access
TWTor D Wager
Tor D Wager
KPK.LUan Phan
K.LUan Phan
ILIsrael Liberzon
Israel Liberzon
STStephan F. Taylor
Stephan F. Taylor

21 February 2018 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
SMShawn M. McClintock
Shawn M. McClintock
IRIrving M. Reti
Irving M. Reti
LCLinda L. Carpenter
Linda L. Carpenter
WMWilliam M. McDonald
William M. McDonald
MDMarc Dubin
Marc Dubin
OTon behalf of both the National Network of Depression Centers rTMS Task Group and the American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments
on behalf of both the National Network of Depression Centers rTMS Task Group and the American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments
To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). Participants included a group of 17 expert clinicians and researchers with expertise in the clinical application of rTMS, representing both the National Network of Depression Centers (NNDC) rTMS Task Group and the American Psychiatric Association Council on Research (APA CoR) Task Force on Novel Biomarkers and Treatments. The consensus statement is based on a review of extensive literature from 2 databases (OvidSP MEDLINE and PsycINFO) searched from 1990 through 2016. The search terms included variants of major depressive disorder and transcranial magnetic stimulation. The results were limited to articles written in English that focused on adult populations. Of the approximately 1,500 retrieved studies, a total of 118 publications were included in the consensus statement and were supplemented with expert opinion to achieve consensus recommendations on key issues surrounding the administration of rTMS for MDD in clinical practice settings. In cases in which the research evidence was equivocal or unclear, a consensus decision on how rTMS should be administered was reached by the authors of this article and is denoted in the article as "expert opinion." Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy. These consensus recommendations, developed by the NNDC rTMS Task Group and APA CoR Task Force on Novel Biomarkers and Treatments, provide comprehensive information for the safe and effective clinical application of rTMS in the treatment of MDD.

1 November 2017 in The Lancet Psychiatry
Verified
Journal Article
Open access
PHPaul E Holtzheimer
Paul E Holtzheimer
MHMustafa M Husain
Mustafa M Husain
SLSarah Hollingsworth Lisanby
Sarah Hollingsworth Lisanby
STStephan F. Taylor
Stephan F. Taylor
LWLouis A Whitworth
Louis A Whitworth
HMHelen S Mayberg
Helen S Mayberg
Deep brain stimulation (DBS) of the subcallosal cingulate white matter has shown promise as an intervention for patients with chronic, unremitting depression. To test the safety and efficacy of DBS for treatment-resistant depression, a prospective, randomised, sham-controlled trial was conducted. Participants with treatment-resistant depression were implanted with a DBS system targeting bilateral subcallosal cingulate white matter and randomised to 6 months of active or sham DBS, followed by 6 months of open-label subcallosal cingulate DBS. Randomisation was computer generated with a block size of three at each site before the site started the study. The primary outcome was frequency of response (defined as a 40% or greater reduction in depression severity from baseline) averaged over months 4-6 of the double-blind phase. A futility analysis was performed when approximately half of the proposed sample received DBS implantation and completed the double-blind phase. At the conclusion of the 12-month study, a subset of patients were followed up for up to 24 months. The study is registered at ClinicalTrials.gov, number NCT00617162. Before the futility analysis, 90 participants were randomly assigned to active (n=60) or sham (n=30) stimulation between April 10, 2008, and Nov 21, 2012. Both groups showed improvement, but there was no statistically significant difference in response during the double-blind, sham-controlled phase (12 [20%] patients in the stimulation group vs five [17%] patients in the control group). 28 patients experienced 40 serious adverse events; eight of these (in seven patients) were deemed to be related to the study device or surgery. This study confirmed the safety and feasibility of subcallosal cingulate DBS as a treatment for treatment-resistant depression but did not show statistically significant antidepressant efficacy in a 6-month double-blind, sham-controlled trial. Future studies are needed to investigate factors such as clinical features or electrode placement that might improve efficacy. Abbott (previously St Jude Medical).

1 April 1999 in Biological Psychiatry
Verified
Journal Article
Closed access
ILIsrael Liberzon
Israel Liberzon
STStephan F. Taylor
Stephan F. Taylor
RARichard Amdur
Richard Amdur
TJTara D Jung
Tara D Jung
KCKenneth R Chamberlain
Kenneth R Chamberlain
LFLorraine M Fig
Lorraine M Fig

1 July 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
AWAnne Weigand
Anne Weigand
Andreas HornAndreas Horn
Andreas Horn
RCRuth Caballero
Ruth Caballero
DCDanielle Cooke
Danielle Cooke
ASAdam P. Stern
Adam P. Stern
MFMichael D. Fox
Michael D. Fox